J. Melhorn

发表

Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey

N. Rahman, H. Iftikhar, A. Aujayeb, 2022, European Respiratory Journal.

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

I. Pavord, T. Hinks, S. Ramakrishnan, 2021, Thorax.

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 - the ATOMIC2 trial

J. Underwood, D. Lasserson, S. Dutton, 2021, medRxiv.

Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus.

J. Ward, J. Fox, D. Haines, 1996, Laboratory animal science.

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

I. Pavord, N. Rahman, D. Lasserson, 2020, Trials.

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

I. Pavord, J. Underwood, D. Lasserson, 2021, The Lancet Respiratory Medicine.

A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial

I. Pavord, J. Underwood, D. Lasserson, 2021, SSRN Electronic Journal.

COVID-19 and pneumothorax: a multicentre retrospective case series

H. Davies, M. Kokosi, M. Spiro, 2020, European Respiratory Journal.

The Management of Subcutaneous Emphysema in Pneumothorax: A Literature Review

H. Davies, J. Melhorn, 2021, Current Pulmonology Reports.

Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection

A. Mentzer, N. Petousi, A. Fries, 2023, Frontiers in Medicine.

Take a Deep Breath — Time to Plunge into Inducible Laryngeal Obstruction

I. Pavord, J. Melhorn, Jordan Thomas, 2022, NEJM Evidence.